Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.12.5917

Hepatitis C Virus - Proteins, Diagnosis, Treatment and New Approaches for Vaccine Development  

Keyvani, Hossein (Department of Clinical Virology, Tehran University of Medical Sciences)
Fazlalipour, Mehdi (Department of Medical Virology, Tehran University of Medical Sciences)
Monavari, Seyed Hamid Reza (Department of Clinical Virology, Tehran University of Medical Sciences)
Mollaie, Hamid Reza (Department of Medical Virology, Tehran University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.12, 2012 , pp. 5917-5935 More about this Journal
Abstract
Background: Hepatitis C virus (HCV) causes acute and chronic human hepatitis infection and as such is an important global health problem. The virus was discovered in the USA in 1989 and it is now known that three to four million people are infected every year, WHO estimating that 3 percent of the 7 billion people worldwide being chronically infected. Humans are the natural hosts of HCV and this virus can eventually lead to permanent liver damage and carcinoma. HCV is a member of the Flaviviridae family and Hepacivirus genus. The diameter of the virus is about 50-60 nm and the virion contains a single-stranded positive RNA approximately 10,000 nucleotides in length and consisting of one ORF which is encapsulated by an external lipid envelope and icosahedral capsid. HCV is a heterogeneous virus, classified into 6 genotypes and more than 50 subtypes. Because of the genome variability, nucleotide sequences of genotypes differ by approximately 31-34%, and by 20-23% among subtypes. Quasi-species of mixed virus populations provide a survival advantage for the virus to create multiple variant genomes and a high rate of generation of variants to allow rapid selection of mutants for new environmental conditions. Direct contact with infected blood and blood products, sexual relationships and availability of injectable drugs have had remarkable effects on HCV epidemiology. Hundreds of thousands of people die each year from hepatitis and liver cancer caused by HCV virus infection. Approximately 80% of patients with acute hepatitis C progress into a chronic disease state leading to serious hepatic disorders, 10-20% of which develop chronic liver cirrhosis and hepatocellular carcinoma. The incubation period of HCV is 6-8 weeks and the infection is often asymptomatic so it is very hard to detect at early stages, making early treatment very difficult. Therefore, hepatitis C is called a "silent disease". Neutralizing antibodies are produced against several HCV proteins during infection but the virus mutates to escape from antibodies. Some patients with chronic hepatitis C may have some symptoms such as fatigue, muscle aches, nausea and pain. Autoimmune and immunecomplex-mediated diseases have also been reported with chronic HCV infection.
Keywords
Hepatitis C Virus; treatment; vaccine; virus like particle;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kanto T, Hayashi N, Takehara T, et al (1995). Serial density analysis of hepatitis C virus particle populations in chronic hepatitis C patients treated with interferon-alpha. J Med Virol, 46, 230-7.   DOI   ScienceOn
2 Katsarou K, Serti E, Tsitoura P, et al (2009). Green fluorescent protein - Tagged HCV non-enveloped capsid like particles: Development of a new tool for tracking HCV core uptake. Biochimie, 91, 903-15.   DOI   ScienceOn
3 Kim H, Mazumdar B, Bose SK, et al (2012). Hepatitis C Virus Mediated Inhibition of Cathepsin S Increases Invariant Chain Expression on Hepatocyte Cell Surface. J Virol, 36, 56-9.
4 Kim KH, Hong SP, Kim K, et al (2007). HCV core protein induces hepatic lipid accumulation by activating SREBP1 and $PPAR{\gamma}$. Biochem and Biophysic Res Com, 355, 883-8.   DOI   ScienceOn
5 Klade CS, Schuller E, Boehm T, et al (2012). Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination. Vaccine, 30, 2943-50.   DOI   ScienceOn
6 Klevens RM, Hu DJ, Jiles R, et al (2012). Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis, 55, 3-9.   DOI
7 Guo X, Zhao Z, Xie J, et al (2012). Prediction of response to pegylated-interferon- inverted question mark and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype. Virol J, 9, 123-5.   DOI
8 Gupta G, Qin H, Song J (2012). Intrinsically Unstructured Domain 3 of Hepatitis C Virus NS5A Forms a "Fuzzy Complex" with VAPB-MSP Domain Which Carries ALS-Causing Mutations. PLoS One, 7, 39261-4.   DOI
9 Haller AA, Lauer GM, King TH, et al (2007). Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine, 25, 1452-63.   DOI   ScienceOn
10 Yamanaka T, Uchida M, Doi T (2002). Innate form of HCV core protein plays an important role in the localization and the function of HCV core protein. Biochemical and Biophysical Res Communications, 294, 521-7.   DOI   ScienceOn
11 Yang X-J, Liu J, Ye L, et al (2006). HCV NS2 protein inhibits cell proliferation and induces cell cycle arrest in the S-phase in mammalian cells through down-regulation of cyclin A expression. Virus Res, 121, 134-43.   DOI   ScienceOn
12 Ye L, Li J, Zhang T, et al (2012). Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells. Virus Res, 65, 65-9.
13 Yoo D, Song C, Sun Y, et al (2010). Modulation of host cell responses and evasion strategies for porcine reproductive and respiratory syndrome virus. Virus Res, 154, 48-60.   DOI   ScienceOn
14 Zeisel MB, Baumert TF (2006). Production of infectious hepatitis C virus in tissue culture: A breakthrough for basic and applied research. J Hepatology, 44, 436-9.   DOI   ScienceOn
15 Zeng J, Wu Y, Liao Q, Li L, Chen X (2012). Liver X receptors agonists impede hepatitis C virus infection in an Idol-dependent manner. Antiviral Res, 85, 36-9.
16 Zeng R, Li G, Ling S, et al (2009). A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice. Antiviral Res, 84, 23-30.   DOI   ScienceOn
17 Zeremski M, Makeyeva J, Arasteh K, et al (2012). Hepatitis C virusspecific immune responses in noninjecting drug users. J Viral Hepat, 19, 554-9.   DOI   ScienceOn
18 Harris SJ, Woodrow SA, Gearing AJH, et al (1996). The effects of adjuvants on CTL induction by V3:Ty-virus-like particles (V3- VLPs) in mice. Vaccine, 14, 971-6.   DOI   ScienceOn
19 Hamdy S, Haddadi A, Hung RW, Lavasanifar A (2011). Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Advanced Drug Delivery Reviews, 63, 943-55.   DOI   ScienceOn
20 Hanumantha RN, Baji BP, Rajendra L, et al (2011). Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles. Vaccine, 29, 7326-34.   DOI   ScienceOn
21 Hechtfischer A, Meier-Ewert H, Marschall M (1999). A persistent variant of influenza C virus fails to interact with actin filaments during viral assembly. Virus Res, 61, 113-24.   DOI   ScienceOn
22 Honda A, Hatano M, Kohara M, et al (2000). HCV-core protein accelerates recovery from the insensitivity of liver cells to Fasmediated apoptosis induced by an injection of anti-Fas antibody in mice. J Hepatology, 33, 440-7.   DOI   ScienceOn
23 Hourioux C, Ait-Goughoulte M, Patient R, et al (2007). Core protein domains involved in hepatitis C virus-like particle assembly and budding at the endoplasmic reticulum membrane. Cell Microbiol, 9, 1014-27.   DOI   ScienceOn
24 Hsieh MJ, Lan KP, Liu HY, et al (2012). Hepatitis C virus E2 protein involve in insulin resistance through an impairment of Akt/PKB and GSK3ss signaling in hepatocytes. BMC Gastroenterol, 12, 74.   DOI
25 Huang YJ, Kobayashi J,Yoshimura T (2002). Genome mapping and gene analysis of Antheraea pernyi nucleopolyhedrovirus for improvement of baculovirus expression vector system. J Bioscience and Bioengineering, 93, 183-91.   DOI
26 Huang Z-S, Wang C-C, Wu H-N (2010). HCV NS3 protein helicase domain assists RNA structure conversion. FEBS Letters, 584, 2356-62.   DOI   ScienceOn
27 Zielonka A, Gedvilaite A, Ulrich R, et al (2006). Generation of viruslike particles consisting of the major capsid protein VP1 of goose hemorrhagic polyomavirus and their application in serological tests. Virus Res, 120, 128-37.   DOI   ScienceOn
28 Zhang K, Tan WJ, Deng Y, et al (2008). Development of infectious pseudo-particle harboring three subtypes hepatitis C virus glycoproteins and their application in neutralization assays. Bing Du Xue Bao, 24, 287-94.
29 Zhao Y, Sanchez A, Nie X, et al (2008). A highly sensitive and reproducible HCV RNA hybridization method valuable for antiviral drug discovery. J Virological Methods, 151, 154-7.   DOI   ScienceOn
30 Zheng X, Pang M, Chan A, et al (2003). Direct comparison of hepatitis C virus genotypes tested by INNO-LiPA HCV II and TRUGENE HCV genotyping methods. J Clinical Virology, 28, 214-6.   DOI   ScienceOn
31 Zuo G, Li Z, Chen L, Xu X (2007). Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. Antiviral Res, 76, 86-92.   DOI   ScienceOn
32 Tan Y-J, Lim S-P, Ng P, et al (2003). CD81 engineered with endocytotic signals mediates HCV cell entry: implications for receptor usage by HCV in vivo. Virology, 308, 250-69.   DOI   ScienceOn
33 Tanaka M, Fujiyama S, Itoh K, et al (2004). Clinical usefulness of a new hepatitis C virus RNA extraction method using specific capture probe and magnetic particle in hemodialysis patients. Ther Apher Dial, 8, 328-34.   DOI   ScienceOn
34 Tang J, Lee K, Bothner B, et al (2009). Dynamics and Stability in Maturation of a Virus. J Molecular Biology, 392, 803-12.   DOI   ScienceOn
35 Thuman-Commike PA, Greene B, Malinski JA, et al (1999). Mechanism of scaffolding-directed virus assembly suggested by comparison of scaffolding-containing and scaffolding-lacking p22 procapsids. Biophysical J, 76, 3267-77.   DOI   ScienceOn
36 Falcon V, Garcia C, Rosa M, et al (1999). Ultrastructural and immunocytochemical evidences of core-particle formation in the methylotrophicPichia pastorisyeast when expressing HCV structural proteins (core-E1). Tissue and Cell, 31, 117-25.   DOI   ScienceOn
37 Huet C, Dabis F (2000). Transmission intra-familiale du virus de l'hepatite C dans le contexte de l'infection par le virus de l'immunodeficience humaine: actualites et implications pour le depistage. Medecine et Maladies Infectieuses, 30, 769-72.   DOI   ScienceOn
38 Huret C, Desjardins D, Miyalou M, et al (2012). Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice. Vaccine, 25, 156-9.
39 Falcon V, Acosta-Rivero N, Chinea G, et al (2003). Nuclear localization of nucleocapsid-like particles and HCV core protein in hepatocytes of a chronically HCV-infected patient. Biochemical and Biophysical Res Communications, 310, 54-8.   DOI   ScienceOn
40 Fane BA, Prevelige Jr PE (2003). Mechanism Of Scaffolding- Assisted Viral Assembly. In C Wah and E J John (Eds.). Advances in Protein Chemistry, 64, 259-99.   DOI
41 Feinstone SM, Hu DJ,Major ME (2012). Prospects for prophylactic and therapeutic vaccines against hepatitis C virus. Clin Infect Dis, 55, 25-32.   DOI
42 Firbas C, Boehm T, Buerger V, et al (2010). Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. Vaccine, 28, 2397-407.   DOI   ScienceOn
43 Firbas C, Jilma B, Tauber E, et al (2006). Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine, 24, 4343-53.   DOI   ScienceOn
44 van Oers MM (2006). Vaccines for viral and parasitic diseases produced with baculovirus vectors. In K M Bryony C. Bonning & J S Aaron (Eds.), Advances in Virus Res, 68, 193-253.   DOI
45 Tobin GJ, Battles JK, Rasmussen L, et al (1995). [15] Assembly of recombinant retroviral gag precursors into pseudovirions in the baculovirus-insect cell expression system. In W A Kenneth (Ed.), Methods in Molecular Genetics, 7, 237-53   DOI
46 Tong X, Malcolm BA (2006). Trans-complementation of HCV replication by non-structural protein 5A. Virus Res, 115, 122-30.   DOI   ScienceOn
47 Uno-Furuta S, Matsuo K, Tamaki S, et al (2003). Immunization with recombinant Calmette-Guerin bacillus (BCG)-hepatitis C virus (HCV) elicits HCV-specific cytotoxic T lymphocytes in mice. Vaccine, 21, 3149-56.   DOI   ScienceOn
48 Velazquez VM, Hon H, Ibegbu C, et al (2012). Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection. Hepatology, 39, 36-9.
49 Vermehren J, Yu M-L, Monto A, et al (2011). Multi-center evaluation of the Abbott RealTime HCV Assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clinical Virology, 52, 133-7.   DOI   ScienceOn
50 Vidalin O, Fournillier A, Renard N, et al (2000). Use of conventional or replicating nucleic acid-based vaccines and recombinant semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens. Virology, 276, 259-70.   DOI   ScienceOn
51 Wang Y, Xia X, Li C, et al (2009). A new HCV genotype 6 subtype designated 6v was confirmed with three complete genome sequences. J Clinical Virology, 44, 195-9.   DOI   ScienceOn
52 Wegzyn CM, Wyles DL (2012). Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). Current Opinion in Pharmacology, 23, 450-9.
53 Furusyo N, Ogawa E, Sudoh M, et al (2012). Raloxifene hydrochloride as a novel antiviral agent: inhibition of hepatitis C virus (HCV) replication. J Hepatology, 56, 438-40.
54 Fouad SA, Esmat S, Omran D, et al (2012). Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection. World J Gastroenterol, 18, 2988-994.   DOI   ScienceOn
55 Frey SE, Houghton M, Coates S, et al (2010). Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine, 28, 6367-73.   DOI   ScienceOn
56 Fujiwara K, Allison RD, Wang RY, et al (2012). Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology, 46, 31-42.
57 Futatsumori-Sugai M, Tsumoto K (2010). Signal peptide design for improving recombinant protein secretion in the baculovirus expression vector system. Biochemical and Biophysical Res Communications, 391, 931-5.   DOI   ScienceOn
58 Gal-Tanamy M, Walker C, Foung S, et al (2009). Chapter 24 - Hepatitis C. In D T B Alan and R S Lawrence (Eds.), Vaccines for biodefense and emerging and neglected diseases. London: Academic Press. 413-440.
59 Gelberg L, Robertson MJ, Arangua L, et al (2012). Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in los angeles. Public Health Rep, 127, 407-21.
60 Goldmann C, Stolte N, Nisslein T, et al (2000). Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus. J Virological Methods, 90, 85-90.   DOI   ScienceOn
61 Gunson RN, Shouval D, Roggendorf M, et al (2003). Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clinical Virology, 27, 213-30.   DOI   ScienceOn
62 Roldao A, Vieira HLA, Charpilienne A, et al (2007). Modeling rotavirus-like particles production in a baculovirus expression vector system: Infection kinetics, baculovirus DNA replication, mRNA synthesis and protein production. J Biotechnology, 128, 875-94.   DOI   ScienceOn
63 Wu X, Ishaq M, Hu J, Guo D (2008). HCV NS3/4A protein activates HIV-1 transcription from its long terminal repeat. Virus Res, 135, 155-60.   DOI   ScienceOn
64 Roingeard P, Hourioux C, Blanchard E, et al (2004). Hepatitis C virus ultrastructure and morphogenesis. Biology of the Cell, 96, 103-8.   DOI   ScienceOn
65 Roldao A, Silva AC, Mellado M, et al (2011). 1.47-Viruses and Virus- Like Particles in Biotechnology: Fundamentals and Applications. In M-Y Editor-in-Chief: murray (Ed.), Comprehensive Biotechnology (Second Edition), 625-649.
66 Roohvand F, Aghasadeghi M-R, Sadat S M, et al (2007). HCV core protein immunization with Montanide/CpG elicits strong Th1/ Th2 and long-lived CTL responses. Biochemical and Biophysical Res Communications, 354, 641-9.   DOI   ScienceOn
67 Ruzzenenti MR, De Luigi MC, Bruni R, et al (2000). PCR testing for HCV in anti-HCV negative blood donors involved in the so called HCV +ve post-transfusion hepatitis. Transfusion Sci, 22, 161-4.   DOI   ScienceOn
68 Safi AZ, Waheed Y, Sadat J, et al (2012). Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan. Asian Pac J Tropical Biomedicine, 2, 532-6.   DOI   ScienceOn
69 Schlaphoff V, Klade CS, Jilma B, et al (2007). Functional and phenotypic characterization of peptide-vaccine-induced HCVspecific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine, 25, 6793-806.   DOI   ScienceOn
70 Comanor L, Elkin C, Leung K, et al (2003). Successful HCV genotyping of previously failed and low viral load specimens using an HCV RNA qualitative assay based on transcriptionmediated amplification in conjunction with the line probe assay. J Clinical Virology, 28, 14-26.   DOI   ScienceOn
71 Coppola N, Pisapia R, Tonziello G, et al (2009). Improvement in the aetiological diagnosis of acute hepatitis C: A diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clinical Virology, 46, 222-9.   DOI   ScienceOn
72 Counihan NA, Rawlinson SM, Lindenbach BD (2011). Trafficking of hepatitis C virus core protein during virus particle assembly. PLoS Pathog, 7, 10-30.
73 de Vicente J, Hendricks RT, Smith DB, et al (2009). Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: synthesis and structure-activity relationships of benzothiazine-substituted quinolinediones. Bioorganic and amp. Med Chemistry Letters, 19, 3642-6.   DOI   ScienceOn
74 de Witte L, Zoughlami Y, Aengeneyndt B, et al (2008). Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation. Immunobiology, 212, 679-91.   DOI   ScienceOn
75 Delamare C, Carbonne B, Heim N, et al (1999). Detection of hepatitis C virus RNA (HCV RNA) in amniotic fluid: a prospective study. J Hepatology, 31, 416-20.   DOI   ScienceOn
76 Delgui L, Ona A, Gutierrez S, et al (2009). The capsid protein of infectious bursal disease virus contains a functional ${\alpha}4{\beta}1$ integrin ligand motif. Virology, 386, 360-72.   DOI   ScienceOn
77 Desjardins D, Huret C, Dalba C, et al (2009). Recombinant retroviruslike particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development. J Gene Med, 11, 313-25.   DOI   ScienceOn
78 Shi J, Zhou L, Amblard F, et al (2012). Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors. Bioorganic and amp; Med Chemistry Letters, 22, 3488-91.   DOI   ScienceOn
79 Schmeding M, Kienlein S, Rocken C, et al (2010). ELISA-based detection of C4d after liver transplantation - A helpful tool for differential diagnosis between acute rejection and HCVrecurrence? Transplant Immunology, 23, 156-60.   DOI   ScienceOn
80 Scott Muerhoff A,J. Dawson G. (2003). Hepatitis C virus. In K M Ias (Ed.), Perspectives in Medical Virology, 10, 127-71.
81 Sistigu A, Bracci L, Valentini M, et al (2011). Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. Vaccine, 29, 3465-75.   DOI   ScienceOn
82 Song H, Wittman V, Byers A, et al (2010). In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine, 28, 5524-32.   DOI   ScienceOn
83 Speir JA, Johnson JE (2008). Tetraviruses. In B W J M Editors-in- Chief: & M H V V Regenmortel (Eds.), Encyclopedia of Virology (Third Edition) Oxford: Academic Press. 27-37.
84 Steinmann D, Barth H, Gissler B, et al (2004). Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol, 78, 9030-40.   DOI   ScienceOn
85 Nishimura Y, Kamei A, Uno-Furuta S, et al (1999). A single immunization with a plasmid encoding hepatitis C virus (HCV) structural proteins under the elongation factor 1-${\alpha}$ promoter elicits HCV-specific cytotoxic T-lymphocytes (CTL). Vaccine, 18, 675-80.   DOI
86 O'Hagan DT, Singh M, Dong C, et al (2004). Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine, 23, 672-80.   DOI   ScienceOn
87 Eisenbach C, Freyse A, Lupu CM, et al (2006). Multigenotype HCVNS3 recombinant vaccinia viruses as a model for evaluation of cross-genotype immunity induced by HCV vaccines in the mouse. Vaccine, 24, 5140-8.   DOI   ScienceOn
88 Dreux M, Peitschmann T, Granier C, et al (2006). O.171 HDL inhibits HCV neutralisation by CD81-NOB antibodies by stimulating cell entry through activation of the scavenger receptor BI. J Clinical Virology, 36, 52-3.
89 Duan H, Struble E, Zhong L, et al (2010). Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccine-induced antibodies. Vaccine, 28, 4138-44.   DOI   ScienceOn
90 Dummer LA, Conceicao FR, Nizoli LQ, et al (2009). Cloning and expression of a truncated form of envelope glycoprotein D of Bovine herpesvirus type 5 in methylotrophic yeast Pichia pastoris. J Virological Methods, 161, 84-90.   DOI   ScienceOn
91 Erensoy S (2001). Diagnosis of hepatitis C virus (HCV) infection and laboratory monitoring of its therapy. J Clinical Virology, 21, 271-81.   DOI   ScienceOn
92 Eskander EF, Abd-Rabou AA, Yahya SMM, et al (2012). Does interferon and ribavirin combination therapy ameliorate growth hormone deficiency in HCV genotype-4 infected patients? Clinical Biochemistry, 45, 3-6.   DOI   ScienceOn
93 Bossi V, Galli C (2004). Quantitative signal of anti-HCV by an automated assay predicts viremia in a population at high prevalence of hepatitis C virus infection. J Clinical Virology, 30, 45-9.   DOI   ScienceOn
94 Bourne P, Murray-Rust J, Lakey JH (2001). Protein-nucleic acid interactions: Folding and binding. Current Opinion in Structural Biology, 11, 9-10.   DOI   ScienceOn
95 Papa S, Rinaldi M, Mangia A, et al (1998). Development of a multigenic plasmid vector for HCV DNA immunization. Res in Virology, 149, 315-9.   DOI   ScienceOn
96 Palomares-Jerez MF, Nemesio H,Villalain J (2012). Interaction with membranes of the full C-terminal domain of protein NS4B from Hepatitis C virus. Biochim Biophys Acta, 63, 65-9.
97 Palomares LA, Mena JA, Ramirez OT (2012). Simultaneous expression of recombinant proteins in the insect cell-baculovirus system: Production of virus-like particles. Methods, 56, 389-95.   DOI   ScienceOn
98 Pan Y, Wei W, Kang L, et al (2007). NS5A protein of HCV enhances HBV replication and resistance to interferon response. Biochemical and Biophysical Res Communications, 359, 70-5.   DOI   ScienceOn
99 Park S-H, Lee SR, Hyun BH, et al (2008). Codelivery of PEGIFN-${\alpha}$ inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys. Vaccine, 26, 3978-83.   DOI   ScienceOn
100 Patil A, Khanna N (2012). Novel membrane extraction procedure for the purification of hepatitis B surface antigen from Pichia pastoris. J Chromatography B, 898, 7-14.   DOI
101 Piver E, Roingeard P,Pages J-C (2010). The cell biology of hepatitis C virus (HCV) lipid addiction: Molecular mechanisms and its potential importance in the clinic. Int J Biochemistry and amp; Cell Biology, 42, 869-79.   DOI   ScienceOn
102 Poranen MM,Tuma R (2004). Self-assembly of double-stranded RNA bacteriophages. Virus Res, 101, 93-100.   DOI   ScienceOn
103 Pratt JK, Donner P, McDaniel KF, et al (2005). Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-heteroalkyl-4-hydroxyquinolon-3-yl-benzothiadiazines. Bioorganic and amp; Med Chemistry Letters, 15, 1577-82.   DOI   ScienceOn
104 Carreno V, Bartolome J, Castillo I, et al (2012). New perspectives in occult hepatitis C virus infection. World J Gastroenterol, 18, 2887-94.   DOI   ScienceOn
105 Buckwold VE, Wei J, Huang Z, et al (2007). Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Res, 73, 118-25.   DOI   ScienceOn
106 Buonaguro L, Devito C, Tornesello ML, et al (2007). DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with crossclade neutralizing activity. Vaccine, 25, 5968-77.   DOI   ScienceOn
107 Cao C, Shi C, Li P, et al (1996). Diagnosis of hepatitis C Virus (HCV) infection by antigen-capturing ELISA. Clinical and Diagnostic Virology, 6, 137-45.   DOI
108 Carrion JA, Martinez-Bauer E, Crespo G, et al (2009). Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatology, 50, 719-28.   DOI   ScienceOn
109 Chase R, Skelton A, Xia E, et al (2009). A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors. Antiviral Res, 84, 178-84.   DOI   ScienceOn
110 Chatel-Chaix L, Melancon P, Racine ME, et al (2011). Y-box-binding protein 1 interacts with hepatitis C virus NS3/4A and influences the equilibrium between viral RNA replication and infectious particle production. J Virol, 85, 11022-37.   DOI   ScienceOn
111 Chen P-L, Wang M, Ou W-C, et al (2001). Disulfide bonds stabilize JC virus capsid-like structure by protecting calcium ions from chelation. FEBS Letters, 500, 109-13.   DOI   ScienceOn
112 Chen YL, Zacharias J, Vince R, et al (2012). C-6 aryl substituted 4-quinolone-3-carboxylic acids as inhibitors of hepatitis C virus. Bioorg Med Chem, 35, 110-4.
113 Roffi L, Ricci A, Ogliari C, et al (1998). HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatology, 29, 701-6.   DOI   ScienceOn
114 Qiao M, Murata K, Davis AR, et al (2003). Hepatitis C virus-like particles combined with novel adjuvant systems enhance virusspecific immune responses. Hepatology, 37, 52-9.   DOI   ScienceOn
115 Quesnel-Vallieres M, Lemay M, Lapointe N, et al (2008). HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1. J Clinical Virology, 43, 236-40.   DOI   ScienceOn
116 Radaelli A, Bonduelle O, Beggio P, et al (2007). Prime-boost immunization with DNA, recombinant fowlpox virus and VLPSHIV elicit both neutralizing antibodies and $IFN{\gamma}$-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. Vaccine, 25, 2128-38.   DOI   ScienceOn
117 Ma X, Forns X, Gutierrez R, et al (2002). DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine, 20, 3263-71.   DOI   ScienceOn
118 Ma Y, Yates J, Liang Y, et al (2008). NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly. J Virol, 82, 7624-39.   DOI   ScienceOn
119 Mangia A, Cascavilla I, Lezzi G, et al (1997). HCV genotypes in patients with liver disease of different stages and severity. J Hepatology, 26, 1173-8.   DOI   ScienceOn
120 Masalova OV, Atanadze SN, Samokhvalov EI, et al (1998). Detection of hepatitis C virus core protein circulating within different virus particle populations. J Med Virol, 55, 1-6.   DOI   ScienceOn
121 Clarysse C, Van den EC, Nevens F, et al (1995). Genotype, serum level of HCV-RNA and response to interferon-${\alpha}$ treatment in patients with chronic hepatitis C. Netherlands J Med, 47, 265-71.   DOI
122 Chin R, Earnest-Silveira L, Koeberlein B, et al (2008). Recombinant HCV virus like particles to induce humoral and nutralising antibody response to HCV. J Hepatology, 48, 235-7.
123 Ciccaglione AR, Marcantonio C, Equestre M, et al (1998). Secretion and purification of HCV E1 protein forms as glutathione-Stransferase fusion in the baculovirus insect cell system. Virus Res, 55, 157-65.   DOI   ScienceOn
124 Ciotti M, Marcuccilli F, Guenci T, et al (2010). A multicenter evaluation of the Abbott RealTime HCV Genotype II assay. J Virological Methods, 167, 205-7.   DOI   ScienceOn
125 Ampurdanes S, Olmedo E, Maluenda MD, et al (1996). Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatology, 25, 827-32.   DOI   ScienceOn
126 Arase Y, Ikeda K, Chayama K, et al (2001). Efficacy of IFN therapy based on duration period of negative HCV-RNA during IFN administration. Hepatology Res, 19, 22-30.   DOI   ScienceOn
127 Attoui H, Maan S, Anthony SJ, Mertens P (2009). Chapter 3 - Bluetongue virus, other orbiviruses and other reoviruses: Their relationships and taxonomy Bluetongue. London: Academic Press, 23-52
128 Ault KA, Giuliano AR, Edwards RP, et al (2004). A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine, 22, 3004-7.   DOI   ScienceOn
129 Balamurugan V, Renji R, Saha SN, et al (2003). Protective immune response of the capsid precursor polypeptide (P1) of foot and mouth disease virus type 'O' produced in Pichia pastoris. Virus Res, 92, 141-9.   DOI   ScienceOn
130 Matsuo E, Tani H, Lim CK, et al (2006). Characterization of HCVlike particles produced in a human hepatoma cell line by a recombinant baculovirus. Biochemical and Biophysical Res Communications, 340, 200-8.   DOI   ScienceOn
131 Matsuura Y, Tani H, Suzuki K, et al (2001). Characterization of Pseudotype VSV Possessing HCV Envelope Proteins. Virology, 286, 263-75.   DOI   ScienceOn
132 Mavromara P, Sall A, Kalinina O, et al (2005). The impact of HCV diversity on diagnosis tools for HCV infection. Medecine et Maladies Infectieuses, 35, 103-4.   DOI
133 Memarnejadian A, Roohvand F (2010). Fusion of HBsAg and prime/ boosting augment Th1 and CTL responses to HCV polytope DNA vaccine. Cellular Immunology, 261, 93-8.   DOI   ScienceOn
134 Mihailova M, Boos M, Petrovskis I, et al (2006). Recombinant viruslike particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine, 24, 4369-77.   DOI   ScienceOn
135 Mizui M-a, Moriya T, Sasaki F, et al (1994). Relation between HCV genotypes and the prevalence of antibodies against 5-1-1 and C100-3 in Japanese blood donors seropositive for hepatitis C virus. Int Hepatology Communications, 2, 183-5.   DOI
136 Mizukoshi F, Yamamoto T, Mitsuki Y-Y, et al (2009). Activation of HIV-1 Gag-specific CD8+ T cells by yeast-derived VLP-pulsed dendritic cells is influenced by the level of mannose on the VLP antigen. Microbes and Infection, 11, 191-7.   DOI   ScienceOn
137 Mukherjee S, Thorsteinsson MV, Johnston LB, et al (2008). A quantitative description of in vitro assembly of human papillomavirus 16 virus-like particles. J Molecular Biology, 381, 229-37.   DOI   ScienceOn
138 Nakabayashi J (2012). A compartmentalization model of hepatitis C virus replication: An appropriate distribution of HCV RNA for the effective replication. J Theoretical Biology, 300, 110-7.   DOI
139 Bassyouni I, Bassyouni R, Ibrahim N, et al (2012). elevated serum osteopontin levels in chronic hepatitis C virus infection: association with autoimmune rheumatologic manifestations. J Clin Immunol, 36,36-8
140 Barman S, Ali A, Hui EKW, et al (2001). Transport of viral proteins to the apical membranes and interaction of matrix protein with glycoproteins in the assembly of influenza viruses. Virus Res, 77, 61-9.   DOI   ScienceOn
141 Baumert TF, Vergalla J, Satoi J, et al (1999). Hepatitis C viruslike particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology, 117, 1397-407.   DOI   ScienceOn
142 Bellamy AR, Both GW (1990). Molecular biology of rotaviruses. In F a M Karl Maramorosch and S Aaron J (Eds.). Advances in Virus Res, 38, 1-43.   DOI
143 Belyaev AS, Hails RS, Roy P (1995). High-level expression of five foreign genes by a single recombinant baculovirus. Gene, 156, 229-33.   DOI   ScienceOn
144 Bevilacqua E, Fabris A, Floreano P, et al (2009). Genetic factors in mother-to-child transmission of HCV infection. Virology, 390, 64-70.   DOI   ScienceOn
145 Bhatti FA, Amin M, Saleem M (1995). Prevalence of antibody to hepatitis C virus in Pakistani thalassaemics by particle agglutination test utilizing C 200 and C 22-3 viral antigen coated particles. J Pak Med Assoc, 45, 269-71.
146 Blanchard E, Brand D, Roingeard P (2003). Endogenous virus and hepatitis C virus-like particle budding in BHK-21 cells. J Virol, 77, 3888-9.   DOI   ScienceOn
147 Blanchard E, Brand D, Trassard S, et al (2002). Hepatitis C virus-like particle morphogenesis. J Virol, 76, 4073-9.   DOI   ScienceOn
148 Blazevic V, Lappalainen S, Nurminen K, et al (2011). Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine, 29, 8126-33.   DOI   ScienceOn
149 Nguyen H, Sankaran S, Dandekar S (2006). Hepatitis C virus core protein induces expression of genes regulating immune evasion and anti-apoptosis in hepatocytes. Virology, 354, 58-68.   DOI   ScienceOn
150 Newcomb WW, Homa FL, Thomsen DR, et al (2001). In Vitro assembly of the herpes simplex virus procapsid: formation of small procapsids at reduced scaffolding protein concentration. J Structural Biology, 133, 23-31.   DOI   ScienceOn
151 Koev G, Dekhtyar T, Han L, et al (2007). Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro. Antiviral Res, 73, 78-83.   DOI   ScienceOn
152 Korba B, Abigail M, Marc A, et al (2007). Nitazoxanide is an effective antiviral agent against both HBV and HCV replication in vitro. Antiviral Res, 74, 40-3.
153 Kouvatsis V, Argnani R, Tsitoura E, et al (2007). Characterization of herpes simplex virus type 1 recombinants that express and incorporate high levels of HCV E2-gC chimeric proteins. Virus Research, 123, 40-9.   DOI   ScienceOn
154 Krishnadas DK, Li W, Kumar R, et al (2010). HCV-core and NS3 antigens play disparate role in inducing regulatory or effector T cells in vivo: Implications for viral persistence or clearance. Vaccine, 28, 2104-14.   DOI   ScienceOn
155 Lai C-W, Chan Z-R, Yang D-G, et al (2006). Accelerated induction of apoptosis in insect cells by baculovirus-expressed SARS-CoV membrane protein. FEBS Letters, 580, 3829-34.   DOI   ScienceOn
156 Lal SK, Tulasiram P, Jameel S (1997). Expression and characterization of the hepatitis E virus ORF3 protein in the methylotrophic yeast, Pichia pastoris. Gene, 190, 63-7.   DOI   ScienceOn
157 Acosta-Rivero N, Alvarez-Obregon JC, Musacchio A, et al (2002). in vitro self-assembled HCV core virus-like particles induce a strong antibody immune response in sheep. Biochemical and Biophysical Res Communications, 290, 300-4.   DOI   ScienceOn
158 Blutt SE, Warfield KL, O'Neal CM, et al (2006). Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). Vaccine, 24, 1170-9.   DOI   ScienceOn
159 Abacioglu Y H, Davidson F, Simmonds P (1996). Sequence analysis of the 5' non coding region of Turkish HCV isolates: implications for PCR diagnosis. Clinical and Diagnostic Virology, 5, 211-4.   DOI   ScienceOn
160 Acosta-Rivero N, Aguilar JC, Musacchio A, et al (2001). characterization of the HCV Core virus-like particles produced in the methylotrophic yeast pichia pastoris. Biochemical and Biophysical Res Communications, 287, 122-5.   DOI   ScienceOn
161 Acosta-Rivero N, Falcon V, Alvarez C, et al (2003). Structured HCV nucleocapsids composed of P21 core protein assemble primary in the nucleus of Pichia pastoris yeast. Biochemical and Biophysical Res Communications, 310, 48-53.   DOI   ScienceOn
162 Acosta-Rivero N, Rodriguez A, Musacchio A, et al (2004). In vitro assembly into virus-like particles is an intrinsic quality of Pichia pastoris derived HCV core protein. Biochemical and Biophysical Res Communications, 325, 68-74.   DOI   ScienceOn
163 Affranchino JL, Gonzalez SA (2010). In vitro assembly of the feline immunodeficiency virus Gag polyprotein. Virus Res, 150, 153-7.   DOI
164 Ait-Goughoulte M, Hourioux C, Patient R, et al (2006). Core protein cleavage by signal peptide peptidase is required for hepatitis C virus-like particle assembly. J Gen Virol, 87, 855-60.   DOI   ScienceOn
165 Akazawa D, Morikawa K, Omi N, et al (2011). Production and characterization of HCV particles from serum-free culture. Vaccine, 29, 4821-8.   DOI   ScienceOn
166 Lenhard T, Maul G, Haase W, et al (1996). A new set of versatile vectors for the heterologous expression of foreign genes using the baculovirus system. Gene, 169, 187-90.   DOI   ScienceOn
167 Lawitz E, Godofsky E, Rouzier R, et al (2011). Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral Res, 89, 238-45.   DOI   ScienceOn
168 Lee MS, Lebeda FJ,Olson MA (2009). Fold prediction of VP24 protein of Ebola and Marburg viruses using de novo fragment assembly. J Structural Biology, 167, 136-44.   DOI   ScienceOn
169 Lee S, Kim YS, Jo M, et al (2007). Chip-based detection of hepatitis C virus using RNA aptamers that specifically bind to HCV core antigen. Biochemical and Biophysical Res Communications, 358, 47-52.   DOI   ScienceOn
170 Liu F, Ge S, Li L, et al (2012). Virus-like particles: potential veterinary vaccine immunogens. Res Veterinary Sci, 93, 553-9.   DOI   ScienceOn
171 Liu H, Wang D,Yang X (2012). Preparation of polymerisation raspberry-like core-corona composite via heterocoagulated self-assembly based on hydrogen-bonding interaction. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 397, 48-58.   DOI
172 Lorenzo L J, Duenas-Carrera S, Falcon V, et al (2001). Assembly of truncated HCV core antigen into virus-like particles in escherichia coli. Biochemical and Biophysical Res Communications, 281, 962-5.   DOI   ScienceOn
173 Lunsdorf H, Gurramkonda C, Adnan A, et al (2011). Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of the hepatitis B surface antigen. Microb Cell Fact, 10, 48-53.   DOI
174 Alvarez-Obregon JC, Duenas-Carrera S, Valenzuela C, et al (2001). A truncated HCV core protein elicits a potent immune response with a strong participation of cellular immunity components in mice. Vaccine, 19, 3940-6.   DOI   ScienceOn
175 Al Swaff R (2012). Correlation between alanine aminotransferase level, HCV-RNA titer and fibrosis stage in chronic HCV genotype 4 infection. Egyptian J Med Human Genetics, 13, 207-12.   DOI   ScienceOn
176 Albertoni G, Arnoni C P, Araujo PRB, et al (2010). Signal to cut-off (S/CO) ratio and detection of HCV genotype 1 by real-time PCR one-step method: is there any direct relationship? The Brazilian J Infectious Diseases, 14, 147-52.   DOI
177 Alter G, Jost S, Rihn S, et al (2011). Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance. J Hepatology, 55, 278-88.   DOI   ScienceOn
178 Ikejiri M, Ohshima T, Kato K, et al (2007). 5'-O-Masked 2'-deoxyadenosine analogues as lead compounds for hepatitis C virus (HCV) therapeutic agents. Bioorganic and amp; Medicinal Chemistry, 15, 6882-92.   DOI   ScienceOn
179 Ide T, Kumashiro R, Hino T, et al (2002). Short term and two-step interferon therapy for chronic hepatitis C patients with low HCV RNA levels. Hepatology Res, 22, 145-51.   DOI   ScienceOn
180 Idobe-Fujii Y, Ogi N, Hosho K, et al (2006). Hepatocellular carcinoma with sarcomatous change arising after eradication of HCV via interferon therapy. Clinical Imaging, 30, 416-9.   DOI   ScienceOn
181 Iken K, Huang L, Bekele H, et al (2006). Apoptosis of activated CD4+ and CD8+ T cells is enhanced by co-culture with hepatocytes expressing hepatitis C virus (HCV) structural proteins through FasL induction. Virology, 346, 363-72.   DOI   ScienceOn
182 Ivanova L, Le L, Schlesinger MJ (1995). Characterization of revertants of a Sindbis virus 6K gene mutant that affects proteolytic processing and virus assembly. Virus Res, 39, 165-79.   DOI   ScienceOn
183 Januszkiewicz-Lewandowska D, Wysocki J, Rembowska J, et al (2003). Transmission of HCV infection among long-term hospitalized onco-haematological patients. J Hospital Infection, 53, 120-3.   DOI   ScienceOn
184 Jorgensen CM, Lewis CA, Liu J (2012). An analysis of hepatitis C virus-related public inquiries from health professionals: 2009- 2010. Clin Infect Dis, 55, 54-7.
185 Jouan L, Melancon P, Rodrigue-Gervais I, et al. (2010). Distinct antiviral signaling pathways in primary human hepatocytes and their differential disruption by HCV NS3 protease. J Hepatology, 52, 167-75.   DOI   ScienceOn
186 Kamili S, Drobeniuc J, Araujo AC, et al (2012). Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis, 55, 43-8.   DOI